Skip to main content
Premium Trial:

Request an Annual Quote

Caliper Expects Q4 Revenues to Exceed Guidance

NEW YORK (GenomeWeb News) – Caliper Life Sciences said today that based on a preliminary financial review it expects total revenues of $37.6 million for the fourth quarter of 2009, exceeding the company's revenue guidance of $33 to $35 million for the quarter.

The increased revenue figure was a result of stronger-than-anticipated revenues from its IVIS and LabChip products, as well as the benefit of licensing revenues from its recently announced microfluidic licensing deal with Becton Dickinson, which occurred one quarter earlier than anticipated.

Caliper's expected Q4 revenues would also be a 2.5 percent increase over the $36.7 million it reported in the fourth quarter of 2009.

The Hopkinton, Mass.-based firm also said that it expected full-year revenues of $119.6 million in 2009, down 11 percent from the $134.1 million in revenues it reported for 2008.

Caliper said it expects to report cash, cash equivalents, and marketable securities of approximately $38 million and outstanding short-term borrowings of approximately $15 million as of December 31, 2009. In addition, the company said that it expects to report positive operating cash flows on a full-year basis for 2009, one year ahead of previous guidance.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SAR-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.